Brind.

Analysts highlighted bullish calls and raised price targets for AbbVie, Moderna, and Eli Lilly amid sector optimism.

1 report, 1 independent Updated Oct 7

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

AbbVie Moderna Eli Lilly and Company

Keep exploring

The entities involved

AbbVie
pharmaceutical company
- AbbVie announced a joint development partnership with IGI, led by Lida Pacaud.Wed 17:17
- Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.Wed 16:42
Moderna
American biotechnology company
- Scottish Mortgage Investment Trust, managed by Baillie Gifford, highlighted its key holdings in SpaceX and Moderna.Fri 17:13
- Moderna is being led through strategic pivots by CEO Stéphane Bancel.Fri 15:45
Eli Lilly and Company
American pharmaceutical company
- Trade data and legislative control are currently influencing market sentiment and corporate operations.Sat 00:04
- Agreement between Eli Lilly and Hims & Hers Health expands access to Lilly's medicines.Fri 14:13

Related events

AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Jun 8

Coverage

Newest first; wire copies grouped

Oct 7aol.com